Investigational Drug Information for Tegafur
✉ Email this page to a colleague
What is the development status for investigational drug Tegafur?
Tegafur is an investigational drug.
There have been 158 clinical trials for Tegafur.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2014.
The most common disease conditions in clinical trials are Stomach Neoplasms, Adenocarcinoma, and Carcinoma. The leading clinical trial sponsors are Fudan University, Taiho Pharmaceutical Co., Ltd., and National Cancer Institute (NCI).
Summary for Tegafur
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 5,905 |
| WIPO Patent Applications | 134 |
| Japanese Patent Applications | 438 |
| Clinical Trial Progress | Phase 3 (2014-09-01) |
| Vendors | 64 |
Recent Clinical Trials for Tegafur
| Title | Sponsor | Phase |
|---|---|---|
| Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) | Fifth Affiliated Hospital, Sun Yat-Sen University | Phase 2 |
| Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) | Nanfang Hospital, Southern Medical University | Phase 2 |
| Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) | Wuhan University | Phase 2 |
Clinical Trial Summary for Tegafur
Top disease conditions for Tegafur
Top clinical trial sponsors for Tegafur
US Patents for Tegafur
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
